During the past decade, Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 19 clinical trials were completed, i.e. on average, 45.2% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 10 clinical trials were completed. i.e. 47.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 41 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 10 trials sponsored, "University of Bologna" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Incyte Corporation" with 5 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" #1 collaborator was "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are "Chronic Myeloid Leukemia" (7 trials), "Leukemia" (7 trials), "Acute Myeloid Leukemia" (6 trials), "Acute Lymphoblastic Leukemia" (5 trials) and "Multiple Myeloma" (5 trials). Many other conditions were trialed in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" in a lesser frequency.

Most popular intervention types in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are "Drug" (71 trials), "Other" (12 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (4 trials), "Venetoclax" (4 trials), "brentuximab vedotin" (4 trials), "Ibrutinib" (3 trials) and "Imatinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are 90 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi". undefined are not yet recruiting, 17 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 47 completed trials in Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, 5 "Phase 1" clinical trials were conducted, 46 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".